Medtronic's Ablation Explosion and Top-Line Strength Collide with Margin Headwinds
19.06.2026 - 05:57:22 | boerse-global.de
A stunning 124% surge in U.S. heart ablation sales has put Medtronic's product portfolio back in the spotlight, yet the company's stock remains firmly in the red for 2025. Investors, it seems, are less impressed by surgical breakthroughs than by the bottom line.
The medical-device giant reported annual revenue of $36.4 billion for its fiscal 2026, an 8% climb that was powered by a 12% jump in international sales. The U.S. market, by contrast, managed only a 5% gain. Diabetes products, led by the MiniMed insulin pump, and the Evolut transcatheter heart valve system drove much of the demand. But the standout performer was cardiac ablation, where U.S. revenues more than doubled in the latest quarter.
That blistering growth has not translated into shareholder enthusiasm. The stock closed the week near €69, leaving it roughly 15% below its year-end level and well under its long-term 200-day moving average. On Thursday, a modest uptick nudged the shares back above the 50-day line, but analysts at Piper Sandler called the move a "pure recovery attempt" and maintained a Neutral rating with a $85 price target. Across Wall Street, the consensus target is higher at $98, though the wide dispersion of views reflects deep uncertainty.
Should investors sell immediately? Or is it worth buying Medtronic?
The disconnect between operational strength and market performance centers on margins. Medtronic's operating margin slipped to 24.4% in the past fiscal year, a decline of 130 basis points. Heavy investment in new technologies, portfolio restructuring, and tariff-related costs all weighed on profitability. "Strong product growth is no longer enough," the Piper Sandler note argued. "Shareholders want to see earnings improve."
Management is betting that a leaner structure and targeted acquisitions will close the gap. The company completed the initial public offering of its MiniMed unit and is pressing ahead with a full separation of the diabetes business. Recent bolt-on purchases — CathWorks, a developer of coronary imaging software, and Scientia Vascular, a neurovascular device maker — are designed to fill specific product gaps. Meanwhile, the board approved a quarterly dividend increase to $0.72 per share, marking the 49th consecutive annual hike. The payment is scheduled for July 17.
Looking ahead, Medtronic has guided for organic revenue growth of approximately 7% in the new fiscal year and earnings per share of up to $6.00. If those targets are met, the stock could have room to run. But if margins disappoint again, a retest of the year's low is a real risk. For now, the market is watching the cost side of the equation as closely as the revenue line.
Ad
Medtronic Stock: New Analysis - 19 June
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
